Akt signaling in platelets and thrombosis

Expert Review of Hematology

Volumn 3, Issue 1, 2010, Pages 81-91

  Woulfe, Donna S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Akt; Glycogen synthase kinase3; PI3K; Platelet; Thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA3 INTEGRIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4 BISPHOSPHATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 3A; PROTEIN AKT 3; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; THROMBIN; UNCLASSIFIED DRUG;

DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE DELETION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 77953448294     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.75     Document Type: Review

References (92)

1. Jones CI, Bray S, Garner SF et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signalling pathways. Blood 114(7), 1405-1416 (2009).
2. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta 1697, 3-16 (2004).
3. Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. J. Biol. Chem. 275, 27790-27798 (2000).
4. Dittrich M, Birschmann I, Mietner S et al. Platelet protein interactions: map, signaling components, and phosphorylation groundstate. Arterioscler. Thromb. Vasc. Biol. 28, 1326-1331 (2008).
5. Woulfe D, Jiang H, Morgans A et al. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J. Clin. Invest. 113, 441-450 (2004).
6. Chen J, De S, Damron DS et al. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood 104, 1703-1710 (2004).
7. Yin H, Stojanovic A, Hay N et al. The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood 111, 658-665 (2008).
8. Cho H, Thorvaldsen JL, Chu Q et al. Akt1/PKBa is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349-38352 (2001).
9. Cho H, Mu J, Kim JK et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB b). Science 292, 1728-1731 (2001).
10. Boland E, Clayton-Smith J, Woo VG et al. Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/ threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. Am. J. Hum. Genet. 81, 292-303 (2007).
11. Dummler B, Tschopp O, Hynx D et al. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell. Biol. 26, 8042-8051 (2006).
12. Wright GL, Maroulakou IG, Eldridge J et al. VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB J. 22, 3264-3275 (2008).
13. Tschopp O, Yang ZZ, Brodbeck D et al. Essential role of protein kinase B g (PKB g/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132, 2943-2954 (2005).
14. Easton RM, Cho H, Roovers K et al. Role for Akt3/protein kinase Bg in attainment of normal brain size. Mol. Cell. Biol. 25, 1869-1878 (2005).
15. Stahl JM, Sharma A, Cheung M et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010 (2004).
16. Stojanovic A, Marjanovic JA, Brovkovych VM et al. A phosphoinositide 3-kinase-AKT nitric oxide cGMP signaling pathway in stimulating platelet secretion and aggregation. J. Biol. Chem. 281, 16333-16339 (2006).
17. Iwakiri Y, Tsai MH, McCabe TJ et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am. J. Physiol. Heart Circ. Physiol. 282, H2084-H2090 (2002).
18. Furlong B, Henderson AH, Lewis MJ et al. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br. J. Pharmacol. 90, 687-692 (1987).
19. Radomski MW, Palmer RM, Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA 87, 5193-5197 (1990).
20. Radomski MW, Rees DD, Dutra A et al. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br. J. Pharmacol. 107, 745-749 (1992).
21. Resendiz JC, Kroll MH, Lassila R. Protease-activated receptor-induced Akt activation-regulation and possible function. J. Thromb. Haemost. 5, 2484-2493 (2007).
22. Holinstat M, Preininger AM, Milne SB et al. Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates. Mol. Pharmacol. 76, 301-313 (2009).
23. Hunter RW, Harper MT, Hers I. The PKB inhibitor Akti-1/2 potentiates PAR-1-mediated platelet function independently of its ability to block PKB. J. Thromb. Haemost. 6, 1923-1932 (2008).
24. Li Z, Zhang G, Le Breton GC et al. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J. Biol. Chem. 278, 30725-30731 (2003).
25. Freedman JE, Loscalzo J, Benoit SE et al. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J. Clin. Invest. 97, 979-987 (1996).
26. Morrell CN, Matsushita K, Chiles K et al. Regulation of platelet granule exocytosis by S-nitrosylation. Proc. Natl Acad. Sci. USA 102, 3782-3787 (2005).
27. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104, 1606-1615 (2004).
28. Lova P, Paganini S, Hirsch E et al. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. J. Biol. Chem. 278, 131-138 (2003).
29. Carmona G, Gottig S, Orlandi A et al. Role of the small GTPase Rap1 for integrin activity regulation in endothelial cells and angiogenesis. Blood 113, 488-497 (2009).
30. Huston E, Lynch MJ, Mohamed A et al. EPAC, PKA allow cAMP dual control over DNA-PK nuclear translocation. Proc. Natl Acad. Sci. USA 105, 12791-12796 (2008).
31. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274 (2007).
32. Dimmeler S, Fleming I, Fisslthaler B et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605 (1999).
33. Fulton D, Gratton JP, McCabe TJ et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399, 597-601 (1999).
34. Marjanovic JA, Stojanovic A, Brovkovych VM et al. Signaling-mediated functional activation of inducible nitric-oxide synthase and its role in stimulating platelet activation. J. Biol. Chem. 283, 28827-28834 (2008).
35. Marjanovic JA, Li Z, Stojanovic A et al. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J. Biol. Chem. 280, 37430-37438 (2005).
36. Freedman JE, Sauter R, Battinelli EM et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ. Res. 84, 1416-1421 (1999).
37. Gambaryan S, Kobsar A, Hartmann S et al. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J. Thromb. Haemost. 6, 1376-1384 (2008).
38. Riba R, Patel B, Aburima A et al. Globular adiponectin increases cGMP formation in blood platelets independently of nitric oxide. J. Thromb. Haemost. 6, 2121-2131 (2008).
39. Roberts W, Riba R, Homer-Vanniasinkam S et al. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J. Thromb. Haemost. 6, 2175-2185 (2008).
40. Ferreira IA, Mocking AI, Urbanus RT et al. Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B. J. Biol. Chem. 280, 32625-32633 (2005).
41. Kirk RI, Sanderson MR, Lerea KM. Threonine phosphorylation of the b3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding. J. Biol. Chem. 275, 30901-30906 (2000).
42. Lerea KM, Venjara AY, Olson SC et al. Threonine phosphorylation of integrin b3 in calyculin A-treated platelets is selectively sensitive to 5́-iodotubercidin. Biochim. Biophys. Acta 1773, 185-191 (2007).
43. Li D, August S, Woulfe DS. GSK3b is a negative regulator of platelet function and thrombosis. Blood 111, 3522-3530 (2008).
44. Barry FA, Graham GJ, Fry MJ et al. Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett. 553, 173-178 (2003).
45. Imandt L, Genders T, Wessels H et al. The effect of lithium on platelet aggregation and platelet release reaction. Thromb. Res. 11, 297-308 (1977).
46. Zhang W, Colman RW. Thrombin regulates intracellular cAMP concentration in human platelets through phosphorylation/activation of PDE3A. Blood 110(5), 1475-1482 (2007).
47. Hunter R, Hers I. Insulin/IGF-1 hybrid receptor expression on human platelets; consequences for the effect of insulin on platelet function. J. Thromb. Haemost. 7(12), 2123-2130 (2009).
48. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu. Rev. Biochem. 68, 965-1014 (1999).
49. Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr. Opin. Cell Biol. 21, 256-261 (2009).
50. Wick MJ, Dong LQ, Riojas RA et al. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1. J. Biol. Chem. 275, 40400-40406 (2000).
51. Hresko RC, Mueckler M. mTOR RICTOR is the Ser473 kinase for Akt/ protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406-40416 (2005).
52. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
53. Bozulic L, Surucu B, Hynx D et al. PKBa/ Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 30, 203-213 (2008).
54. Kawakami Y, Nishimoto H, Kitaura J et al. Protein kinase C bII regulates Akt phosphorylation on Ser-473 in a cell type-and stimulus-specific fashion. J. Biol. Chem. 279, 47720-47725 (2004).
55. Mao K, Kobayashi S, Jaffer ZM et al. Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes. J. Mol. Cell. Cardiol. 44, 429-434 (2008).
56. Kucera GL, Rittenhouse SE. Human platelets form 3-phosphorylated phosphoinositides in response to a-thrombin, U46619, or GTP g S. J. Biol. Chem. 265, 5345-5348 (1990).
57. Sorisky A, King WG, Rittenhouse SE. Accumulation of PtdIns(3, 4)P2 and PtdIns(3, 4,5)P3 in thrombin-stimulated platelets. Different sensitivities to Ca2+ or functional integrin. Biochem. J. 286(Pt 2), 581-584 (1992).
58. Banfic H, Downes CP, Rittenhouse SE. Biphasic activation of PKBa/Akt in platelets. Evidence for stimulation both by phosphatidylinositol 3, 4-bisphosphate, produced via a novel pathway, and by phosphatidylinositol 3, 4,5-trisphosphate. J. Biol. Chem. 273, 11630-11637 (1998).
59. Kim S, Foster C, Lecchi A et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 99, 3629-3636 (2002).
60. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Ka pathway. Blood 110, 4243-4252 (2007).
61. Angelillo-Scherrer A, Burnier L, Flores N et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J. Clin. Invest. 115, 237-246 (2005).
62. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
63. Hirsch E, Bosco O, Tropel P et al. Resistance to thromboembolism in PI3Kg-deficient mice. FASEB J. 15, 2019-2021 (2001).
64. Lian L, Wang Y, Draznin J et al. The relative role of PLCb and PI3Kg in platelet activation. Blood 106, 110-117 (2005).
65. Schoenwaelder SM, Ono A, Sturgeon S et al. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin a IIb b 3 adhesive function in platelets. J. Biol. Chem. 282, 28648-28658 (2007).
66. Canobbio I, Stefanini L, Cipolla L et al. Genetic evidence for a predominant role of PI3Kb catalytic activity in ITAM-and integrin-mediated signaling in platelets. Blood 114, 2193-2196 (2009).
67. Kim S, Mangin P, Dangelmaier C et al. The role of PI 3-Kb in glycoprotein VI-mediated akt activation in platelets. J. Biol. Chem. 284(49), 33763-33772 (2009).
68. Jackson SP, Schoenwaelder SM, Goncalves I et al. PI 3-kinase p110b: a new target for antithrombotic therapy. Nat. Med. 11, 507-514 (2005).
69. Cosemans JM, Munnix IC, Wetzker R et al. Continuous signaling via PI3K isoforms b and g is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108, 3045-3052 (2006).
70. Kim S, Garcia A, Jackson SP et al. Insulin-like growth factor-1 regulates platelet activation through PI3-Ka isoform. Blood 110, 4206-4213 (2007).
71. Ma K, Cheung SM, Marshall AJ et al. PI(3,4,5)P3 and PI(3, 4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal. 20, 684-694 (2008).
72. Giuriato S, Pesesse X, Bodin S et al. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels. Biochem. J. 376, 199-207 (2003).
73. Maxwell MJ, Yuan Y, Anderson KE et al. SHIP1 and Lyn kinase negatively rRegulate integrin a IIb b 3 signaling in platelets. J. Biol. Chem. 279, 32196-32204 (2004).
74. Severin S, Gratacap MP, Lenain N et al. Deficiency of Src homology 2 domain-containing inositol 5-phosphatase 1 affects platelet responses and thrombus growth. J. Clin. Invest. 117, 944-952 (2007).
75. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J. Biol. Chem. 279, 4186-4195 (2004).
76. Kim S, Jin J, Kunapuli SP. Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. Blood 107, 947-954 (2006).
77. Prudente S, Hribal ML, Flex E et al. The functional Q84R polymorphism of mammalian Tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy. Diabetes 54, 2807-2811 (2005).
78. Andreozzi F, Formoso G, Prudente S et al. TRIB3 R84 variant is associated with impaired insulin-mediated nitric oxide production in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 1355-1360 (2008).
79. Malarstig A, Lindahl B, Wallentin L et al. Soluble CD40L levels are regulated by the-3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler. Thromb. Vasc. Biol. 26, 1667-1673 (2006).
80. Chakrabarti S, Varghese S, Vitseva O et al. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler. Thromb. Vasc. Biol. 25, 2428-2434 (2005).
81. Soranzo N, Rendon A, Gieger C et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood 113, 3831-3837 (2009).
82. George S, Rochford JJ, Wolfrum C et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304, 1325-1328 (2004).
83. Matsui T, Tao J, del Monte F et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104, 330-335 (2001).
84. Fujio Y, Nguyen T, Wencker D et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101, 660-667 (2000).
85. Miyawaki T, Ofengeim D, Noh KM et al. The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death. Nat. Neurosci. 12, 618-626 (2009).
86. Ackah E, Yu J, Zoellner S et al. Akt1/ protein kinase Ba is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 115, 2119-2127 (2005).
87. Camici GG, Steffel J, Amanovic I et al. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur. Heart J. DOI:10.1093/eurheartj/ehp259 (2009) (Epub ahead of print).
88. Sturgeon SA, Jones C, Angus JA et al. Advantages of a selective b-isoform phosphoinositide 3-kinase antagonist, an antithrombotic agent devoid of other cardiovascular actions in the rat. Eur. J. Pharmacol. 587, 209-215 (2008).
89. Medina-Franco JL, Giulianotti MA, Yu Y et al. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening. Bioorg. Med. Chem. Lett. 19, 4634-4638 (2009).
90. Carnero A. Novel inhibitors of the PI3K family. Expert Opin. Investig. Drugs 18(9), 1265-1277 (2009).
91. Yatomi Y, Hazeki O, Kume S et al. Suppression by wortmannin of platelet responses to stimuli due to inhibition of pleckstrin phosphorylation. Biochem. J. 285(Pt 3), 745-751 (1992).
92. Kovacsovics TJ, Bachelot C, Toker A et al. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J. Biol. Chem. 270, 11358-11366 (1995).